CD8A and neoplasm: Therefore, we tried to classify the TME in GCs to better understand tumor–immune interactions and facilitate patient selection for future immunotherapy using CD8+ T cells and PD‐L1 that are currently measured using manual interpretation by pathologists [31] and computational measurements [40].